Global Technologies, LTD Announces Strategic Pivot and New Agreements in Health & Wellness Sector
Over the past 90 days, GTLL has responded proactively to external FDA regulatory shifts that disrupted several industry sectors, including GLP-1 compounding and semaglutide supply. These changes catalyzed GTLL's sharpened focus on the digital health and wellness market, prompting operational streamlining and a commitment to scalable, revenue-focused platforms—particularly through its newly launched subsidiary, Primecare Supply, LLC.
Launch of Primecare Supply and Execution of Key Agreements
As disclosed in its May 30, 2025 Form 8-K filing, GTLL formally launched Primecare Supply, LLC and executed two transformative commercial agreements:
These agreements position Primecare—and GTLL—at the forefront of compliant pharmaceutical distribution and digital wellness innovation.
Leadership Appointments and Strategic Realignment
In line with the Company's refined strategy, H. Wyatt Flippen has been officially appointed Chairman of the Board in addition to his role as Chief Executive Officer. Concurrently, GTLL has removed the President of its clean energy subsidiary, GOe3, LLC, to allow for a full transition away from non-core operations in the EV sector.
'We are building a business that's leaner, more focused, and directly aligned with FDA-compliant pharmaceutical distribution and digital wellness innovation,' said Flippen. 'These agreements and leadership changes reflect our resolve to reduce complexity, expand into higher-growth sectors, and deliver long-term shareholder value.'
A Clearer Path Ahead
GTLL is aggressively expanding its offerings in consumer-facing wellness plans and therapeutic products, leveraging both traditional partnerships and digital infrastructure. The Company is now fully aligned around the growth of its Primecare platform and related ventures, with future announcements anticipated regarding new reseller relationships, patient outreach programs, and proprietary health technologies.
About Global Technologies, LTD
Global Technologies, LTD (OTCPK: GTLL) is a public, multi-operational company committed to building scalable businesses in digital health, wellness, and technology. Through acquisitions, strategic licensing, and integrated platforms, GTLL delivers innovative solutions to improve lives and expand shareholder value.
Forward Looking Statements:
Statements made in this press release that express the Company or management's intentions, plans, beliefs, expectations or predictions of future events, are forward-looking statements. The words 'believe,' 'expect,' 'intend,' 'estimate,' 'anticipate,' 'will' and similar expressions are intended to further identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Those statements are based on many assumptions and are subject to many known and unknown risks, uncertainties and other factors that could cause the Company's actual activities, results or performance to differ materially from those anticipated or projected in such forward-looking statements. The Company cannot guarantee future financial results; levels of activity, performance or achievements and investors should not place undue reliance on the Company's forward-looking statements. No information contained in this press release should be construed as any indication whatsoever of the Company's future financial performance, future revenues or its future stock price. The forward-looking statements contained herein represent the judgment of the Company as of the date of this press release, and the Company expressly disclaims any intent, obligation or undertaking to update or revise such forward-looking statements to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. No information in this press release should be construed as any indication whatsoever of the Company's future revenues or results of operations.
Investor Contact:
Wyatt Flippen, CEO and Chairman of the Board
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
27 minutes ago
- Business Wire
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) ('PharmaCyte' or the 'Company'), today announced the closing of its previously announced $7 million financing. As of April 30, 2025, PharmaCyte had approximately $15.5 million in cash and also holds over $30 million of securities as reflected in the Company's most recent 10K. With the addition of the $7 million in proceeds from this financing, the Company's balance sheet has been further strengthened, providing significant financial flexibility to support its ongoing business initiatives and strategic growth opportunities. 'The successful completion of this financing is a welcome milestone as we continue on our growth trajectory,' said Josh Silverman, Interim Chief Executive Officer of PharmaCyte. 'We expect this additional capital, combined with our substantially reduced operational burn rate and our existing cash position and investments, to bring substantial value to our shareholders as we advance our initiatives and continue to evaluate opportunities that align with our long-term strategy.' As of the date of this release, PharmaCyte has approximately 6.8 million shares of common stock outstanding. Safe Harbor This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of PharmaCyte's management and Board of Directors. Any statements contained in this press release which do not describe historical facts are forward-looking statements subject to risks and uncertainties that could cause actual results, performance, and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, whether our exploration of additional opportunities to create new paths toward shareholder value is successful, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise. More information about PharmaCyte Biotech can be found at
CNBC
28 minutes ago
- CNBC
10 things to watch in the stock market Wednesday including TJX's surge and new Target CEO
The Club's 10 things to watch Wednesday, Aug. 20 — Today's newsletter was written by Investing Club editor Kevin Stankiewicz. 1. Wall Street was set to open slightly lower today after the S & P 500 closed lower yesterday for the third session in a row. Investors were parsing the latest retail earnings this morning. They were also looking ahead to this afternoon's release of the minutes from the Federal Reserve's July meeting — two days before Fed Chairman Jerome Powell addresses the Jackson Hole central bank confab Friday. 2. Shares of TJ Maxx parent TJX Companies are rallying to a new all-time high after second-quarter earnings results beat expectations. Same-store sales were also better than what the Street was expecting. TJX also raised its full-year guide despite tariff headwinds. Consumers want value, and that's what TJX's off-price chains deliver. 3. Target shares tumbled nearly 11% on earnings yet again after the struggling retailer reported another quarter of same-store sales declines and reiterated its full-year outlook. It also announced that Chief Operating Officer Michael Fiddelke will replace longtime CEO Brian Cornell in February. 4. Shares of Lowe's added 3% on the back of better-than-expected quarterly sales and revenue , along with a slight increase to its full-year sales outlook. The home improvement retailer also announced plans to buy drywall and insulation distributor Foundation Building Materials for $8.8 billion. It's a move that mirrors Club name Home Depot's two recent acquisitions to better serve professional customers. 5. McDonald's is cutting the price of combo meals after the fast-food chain was able to convince its franchisees to go along with the plan, The Wall Street Journal reported . It's part of an effort to win back customers who have shied away from the chain in recent years due to rising prices. 6. Club name Amazon's auto sales platform is adding used cars from Hertz , sending shares of the car-rental provider up 10%. Amazon's stock wasn't moving much, unsurprisingly, given that Amazon Autos is a tiny part of the overall company. But with shares of Carvana and Carmax down on the news, investors clearly see the potential for Amazon to grow it. 7. The national average rate on a 30-year fixed-rate mortgage ticked up to 6.68% from last week's 6.67%, and home loan demand stalled. After last week's 23% surge in refinancing applications, refis fell 3% this week. Purchase apps rose 0.1% after last week's 1% increase, according to the latest data from the Mortgage Bankers Association . 8. The FDA approved the first-ever glucose monitoring system specifically for weight loss. The startup Signos makes the system, which uses AI and an off-the-shelf continuous glucose monitor from Dexcom . It can be used as another tool by people taking the GLP-1 drugs from Club name Eli Lilly and Novo Nordisk . But, anyone who wants to lose weight can use the system to help them on their journey. 9. Club name Honeywell is buying a trio of utility software programs from SparkMeter. While these are small deals for Honeywell, the strategic rationale is about enhancing its exposure to growing electricity demand, thanks largely to AI computing. 10. Microsoft will be "an important partner for years to come," OpenAI finance chief Sarah Friar said this morning on CNBC's "Squawk Box." With questions about what OpenAI's push for independence could mean for Club stock Microsoft, Friar's comments are notable. Their evolving and reportedly tense relationship is one of the biggest stories in tech and AI . Sign up for my Top 10 Morning Thoughts on the Market email newsletter for free (See here for a full list of the stocks at Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Indianapolis Star
29 minutes ago
- Indianapolis Star
Is your shrimp radioactive? FDA recalls seafood for possible contamination. Where it was sold
Check your shrimp. The Food and Drug Administration is recalling frozen shrimp sold at Walmart for possible radioactive chemical contamination. The FDA advised the recall in an Aug. 19 notice, saying certain raw frozen shrimp products processed by an Indonesian company, PT. Bahari Makmur Sejati (doing business as BMS Foods), had tested positive for Cesium-137, or Cs-137. Walmart sells the products under its Great Value brand. The presence of the chemical element violates the Federal Food, Drug, and Cosmetic Act, said the FDA, as it appears the affected product may have been "prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137 and may pose a safety concern." Here's what we know. Two-pound bags of Great Value brand Frozen Raw Ez Peel Tail-On Farm-Raised White Vannamei Shrimp are subject to the recall. Lot codes and best by dates include the following: According to Walmart, the shrimp products made by PT. Bahari Makmur Sejati were distributed in 13 states. Indiana stores were not among them. But neighboring state Kentucky is. Cs-137 is a radioisotope of cesium, meaning it is a chemical element that emits radiation as it breaks down. It is man-made and is produced by nuclear fission, according to the FDA. In the United States, it is used in medical devices and measurement gauges, such as industrial devices that measure the thickness of materials. Because it is widespread around the globe, trace amounts can be found in the environment, including soil, food and air, said the FDA. Agencies, including the FDA and U.S. Customs & Border Protection, test for, monitor and regulate the presence of the substance due to the risks associated with long-term exposure. Story continues after photo gallery. The FDA said low-level radiation exposure over time can lead to serious health complications. Exposure to Cs-137 alone can cause burns, acute radiation sickness, cancer and death. As a result, the governing agencies restrict potential exposure to lessen the possibility of these long-term impacts. The FDA said the presence of Cs-137 was confirmed in one sample of breaded shrimp, which was denied entry into the United States. "FDA has concluded that the level detected in the breaded shrimp sample could represent a potential health concern for those exposed to this level of Cs-137 from consumption of the shrimp over an extended period of time combined with radiation that exists in the environment and from other sources such as medical procedures," the agency said in a statement. While Cs-137 was only detected in a single shipment thus far, that does not mean other products made by the same manufacturer are not impacted. PT. Bahari Makmur Sejati has been placed on an import alert that prevents any of their food products from entering the United States until it resolves any conditions that could have caused the exposure. Those with packages of the recalled Walmart shrimp at home should throw them away; do not consume them, said the FDA. Distributors and retailers should dispose of the products and should not sell or serve them. Those who fear they may have been exposed to elevated levels of cesium should contact their medical providers. To make a complaint or report an adverse reaction, consumers can visit the FDA's Industry and Consumer Assistance portal. More in news about food: Devour Indy Summerfest 2025 takes flight. The restaurants, special deals and menus you should know
